Arcus Biosciences (RCUS) Equity Ratio (2017 - 2026)

Arcus Biosciences' Equity Ratio history runs 10 years deep, the most recent figure standing at 0.53 for Q1 2026.

• In Q1 2026, Equity Ratio rose 18.77% year-over-year to 0.53; the TTM figure through Mar 2026 stood at 0.53 (up 18.77% YoY), while the FY2025 annual figure was 0.55, up 31.36% from the prior year.
• Equity Ratio was 0.53 for Q1 2026 at Arcus Biosciences, down from 0.55 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.55 in Q4 2025 to a low of 0.42 in Q4 2024.
• Historically, Equity Ratio has averaged 0.48 across 5 years, with a median of 0.5 in 2022.
• The sharpest annual moves came in 2022 and 2025: Equity Ratio decreased 27.36% in 2022, then soared 31.36% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.51 in 2022, then slipped by 16.52% to 0.42 in 2023, then decreased by 0.04% to 0.42 in 2024, then soared by 31.36% to 0.55 in 2025, then declined by 5.13% to 0.53 in 2026.
• The last three Equity Ratio figures came in at 0.53 (Q1 2026), 0.55 (Q4 2025), and 0.45 (Q3 2025), per Business Quant data.